Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 77 clinical trials
Study of Carfilzomib Lenalidomide Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help

lenalidomide
carfilzomib
chemotherapy regimen
cancer
dexamethasone
  • 0 views
  • 03 Jun, 2021
  • 1 location
To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma.

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.

hydroxyurea
carfilzomib
lenalidomide
myelodysplastic syndromes
multiple myeloma
  • 0 views
  • 17 Jun, 2021
  • 10 locations
Comparation of Chidamide Plus VRD (Bortezomib Lenalidomide Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients

In the phase I trial, dose escalation of chidamide will be performed at 4 different dosages (15mg, 20mg, 25mg, 30mg) for optimal dosage, in the phase II trial, the safety and efficacy of chidamide+VRD will be compared with that of VRD regimen.

lenalidomide
bortezomib
neutrophil count
velcade
plasmacytoma
  • 2 views
  • 23 Jan, 2021
  • 1 location
Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)

This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT053 CAR-BCMA T in patients with relapsed and/or refractory multiple myeloma.

autograft
bcma
line of therapy
proteasome inhibitor
fludarabine
  • 0 views
  • 26 Jan, 2021
  • 2 locations
Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

and bortezomib in adults with relapsed/refractory multiple myeloma (MM).

measurable disease
bortezomib
cancer
refractory multiple myeloma
dexamethasone
  • 0 views
  • 18 Jul, 2021
  • 7 locations
A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)

hematopoietic stem and progenitor cells exposed to transduction with a lentiviral vector driving myeloid-specific interferon-2 expression, which will be administered to up to 9 patients affected by multiple

  • 0 views
  • 12 Feb, 2021
  • 1 location
APG-2575 Monotherapy or in Combination With Lenalidomide / Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

dexamethasone (d) in patients with relapsed/refractory (R/R) multiple myeloma (MM). The primary objective is to evaluate the safety and tolerability, identify dose-limiting toxicities (DLT), the maximum

  • 0 views
  • 07 May, 2021
  • 1 location
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) administered once a day (QD) as a single agent and in combination with dexamethasone.

b-cell lymphoma
t-cell lymphoma
progressive disease
bone marrow procedure
follicular lymphoma
  • 0 views
  • 09 Jul, 2021
  • 13 locations
A Phase 1/2 Open-label Multicenter Dose Escalation and Dose Expansion Study of the Safety Tolerability and PK of HPN217 in Patients With R/R MM

An open-label, Phase 1/2 study of HPN217 as monotherapy to assess the safety, tolerability and PK in patients with relapsed/ refractory multiple myeloma

measurable disease
proteasome inhibitor
neutrophil count
refractory multiple myeloma
platelet count
  • 6 views
  • 18 Mar, 2021
  • 9 locations
Ixazomib + Pomalidomide + Dexamethasone In MM

This is a Phase I/II study using the combination of twice weekly ixazomib plus pomalidomide and dexamethasone in relapsed and or refractory multiple myeloma (RRMM) patients.

immunomodulatory imide drug
proteasome inhibitor
platelet count
imid
pomalyst
  • 0 views
  • 25 Feb, 2021